
KYTX Stock Forecast & Price Target
KYTX Analyst Ratings
Bulls say
Kyverna Therapeutics Inc is demonstrating increasing confidence in the efficacy and safety of its lead product candidate, KYV-101, positioned for myasthenia gravis (MG), with a raised probability of approval reflecting improved clinical outcomes. The company is also witnessing positive early signals in treating refractory rheumatoid arthritis (RA) and multiple sclerosis (MS), indicating a broadening applicability of its CAR T-cell therapies beyond traditional treatment lines. This favorable data trend supports a positive long-term outlook for KYV-101, bolstering investor confidence and prompting revisions in price targets.
Bears say
Kyverna Therapeutics Inc faces significant challenges that contribute to a negative outlook on its stock, primarily due to concerns regarding the efficacy and durability of its lead product candidate, KYV-101. Despite initial positive responses in clinical trials, the potential lack of durable responses for patients, particularly in lupus nephritis (LN) and myasthenia gravis (MG), raises questions about the long-term viability of the treatment. Additionally, there is apprehension regarding the ability to generate positive data for KYV-101 in specific indications, as well as risks associated with potential long-term dilution, which could affect shareholder value.
This aggregate rating is based on analysts' research of Kyverna Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
KYTX Analyst Forecast & Price Prediction
Start investing in KYTX
Order type
Buy in
Order amount
Est. shares
0 shares